Markets:

Overview

News

Currencies

International

Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

197.23 -5.80 (-2.86%)

Streaming Delayed Price Updated: 3:31 PM EST, Mar 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Natera (NTRA) Stock Trades Up, Here Is Why

March 03, 2026

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 4.3% in the afternoon session after Canaccord Genuity reiterated its Buy rating...

Via StockStory

Topics Economy

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗

February 28, 2026

The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics.

Via The Motley Fool

Topics Lawsuit

Why Natera (NTRA) Shares Are Falling Today

February 27, 2026

Shares of genetic testing company Natera (NASDAQ:NTRA). fell 8.3% in the afternoon session after the release of a key inflation report revealed prices paid to U.S. producers rose more than anticipated...

Via StockStory

Topics Earnings Economy

Natera (NTRA) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

Natera (NTRA) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Natera Inc. (NASDAQ:NTRA) Crushes Q4 Earnings Estimates with Strong Oncology Growth ↗

February 26, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Natera Earnings: What To Look For From NTRA

February 24, 2026

Genetic testing company Natera (NASDAQ:NTRA). will be reporting results this Thursday afternoon. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence World Trade

Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks ↗

February 21, 2026

These two stocks are core holdings in the legendary investor's portfolio.

Via The Motley Fool

Topics Artificial Intelligence Earnings

2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds

January 25, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth

January 13, 2026

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an...

Via MarketMinute

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that...

Via MarketMinute

2 Cash-Heavy Stocks to Keep an Eye On and 1 We Question

January 10, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

3 Growth Stocks with Explosive Upside

December 28, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

Topics Energy

3 Reasons We’re Fans of Natera (NTRA)

December 23, 2025

Over the past six months, Natera has been a great trade, beating the S&P 500 by 24.2%. Its stock price has climbed to $235.65, representing a healthy 37.1% increase. This was partly thanks to its solid...

Via StockStory

Topics Stocks

3 Market-Beating Stocks Worth Your Attention

December 22, 2025

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the...

Via StockStory

3 Cash-Producing Stocks with Solid Fundamentals

December 01, 2025

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.

Via StockStory

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗

November 30, 2025

Stanley Druckenmiller is considered one of the greatest investors of all time.

Via The Motley Fool

Topics Artificial Intelligence

Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know

November 24, 2025

A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.

Via StockStory

Topics Economy Government

Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

November 23, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy

Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3

November 19, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the...

Via StockStory

Topics Artificial Intelligence

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds

November 11, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the...

Via StockStory

Topics Stocks

2 Surging Stocks with Impressive Fundamentals and 1 We Question

November 10, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Via StockStory

Natera (NTRA) Q3 2025 Earnings Call Transcript ↗

November 09, 2025

Natera (NTRA) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase

November 07, 2025

Genetic testing company Natera (NASDAQ:NTRA). beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue guidance of $2.22...

Via StockStory

Natera Inc (NASDAQ:NTRA) Q3 2025 Earnings: Revenue Soars Past Estimates, Shares Climb on Raised Guidance ↗

November 06, 2025

Natera (NTRA) Q3 2025 results beat revenue forecasts with $592.2M, driven by strong oncology test growth. The company raised its full-year 2025 guidance.

Via Chartmill

Natera (NASDAQ:NTRA) Delivers Impressive Q3

November 06, 2025

Genetic testing company Natera (NASDAQ:NTRA). reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Delivering useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/pages/Cabling-Installation-and-Maintenance/298118662118

https://www.instagram.com/cim_magazine/

https://www.linkedin.com/company/3962332

http://twitter.com/CABLINGMAG

Affiliated Brands

DATA CENTER FRONTIER

ISE

LIGHTWAVE

DIGITAL INFRASTRUCTURE GROUP

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions